Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894577 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
A Phase 3 study, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,453
- Enrollment target
NCT05894577 is a Phase 3 study that has completed, run by Susanna Naggie, MD. The registered enrollment target is 1,453 participants.
The verdict
NCT05894577, a Phase 3 study, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,453 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID.
Interventions
- OTHER Placebo
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,453 participants |
| Start Date | 2023-01-27 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894577
The ClinicalTrials.gov registry entry for NCT05894577 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susanna Naggie, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05894577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05894577 about?
NCT05894577 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT05894577?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,453 participants. The study started on 2023-01-27. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT05894577?
The interventions under investigation include: Placebo (OTHER), Montelukast (DRUG).
Who is sponsoring clinical trial NCT05894577?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.